Last updated 5 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
America faces a public health emergency of unprecedented scale: the opioid overdose crisis.
While synthetic opioids like fentanyl are often the immediate agents of death, an insidious force is also killing thousands: stigma. This set of negative beliefs rooted in the misconception that addiction is a moral failure creates fundamental barriers to national recovery.
The language we use perpetuates this deadly stigma. A conscious, collective shift in our words isn’t political correctness, it’s a life-saving intervention.
The Opioid Crisis: Three Waves of Devastation
The crisis reveals stigma’s urgency. The Centers for Disease Control and Prevention identifies three distinct, overlapping phases of the opioid epidemic, with each phase representing a shift in the primary driver of overdose deaths.
Wave 1: Rise of Prescription Opioids (1990s)
The first wave began in the 1990s with dramatic increases in opioid painkiller prescribing. Historically, physicians prescribed these medications sparingly due to known addiction risks. However, driven by extensive pharmaceutical marketing and a cultural shift to treat pain more assertively, prescription rates soared.
The FDA approval and launch of OxyContin in 1995-1996 was a key inflection point. By 2012, the national average reached a staggering 81.2 opioid prescriptions for every 100 people. This flood of legal opioids led to widespread nonmedical use and illegal distribution through “pill mills.” Overdose deaths involving prescription opioids nearly quadrupled between 1999 and 2009.
Wave 2: The Shift to Heroin (2010)
As federal and state authorities cracked down on pill mills and implemented policies to curb overprescribing, prescription opioid supply tightened. However, this didn’t address underlying demand from millions who had already developed opioid use disorder. Many turned to a cheaper, more readily available alternative: heroin.
Wave 3: The Fentanyl Era (2013-Present)
The current and most lethal wave is defined by proliferation of potent, illicitly manufactured synthetic opioids, primarily fentanyl and its chemical analogs. Fentanyl is 50 to 100 times more potent than morphine and is often mixed with other drugs or pressed into counterfeit pills made to look like legitimate prescriptions like Xanax or Adderall.
This leads to high risk of unintentional overdose, as many people are unaware they’re consuming the deadly substance.
The progression through these waves reveals a critical lesson about public policy. The initial response focused heavily on supply-side interventions, restricting prescription pill availability. While well-intentioned, this approach failed to simultaneously scale up demand-side solutions: addiction treatment and harm reduction services.
The demand for opioids, driven by untreated chronic medical conditions, didn’t vanish when pill supply was constrained. Instead, vulnerable populations were pushed from a regulated, albeit overprescribed, drug supply to a far more dangerous illicit market.
The Human Cost
The crisis’s human and economic cost is immense.
In 2023 alone, approximately 105,000 people died from drug overdoses in the United States. Nearly 80,000 of those deaths, about 76%, involved opioids. This translates to an average of 217 people dying from opioid overdoses every day.
From 1999 to 2023, more than 806,000 people in the U.S. have died from opioid overdoses.
There are signs of progress. Provisional CDC data indicates a remarkable, nearly 27% decrease in predicted drug overdose deaths in 2024 compared to 2023. This decline suggests expanded public health interventions, such as increased naloxone distribution and access to treatment, are having meaningful impact.
However, drug overdose remains a leading cause of death for Americans aged 18-44.
One analysis from the Joint Economic Committee determined the opioid epidemic cost the U.S. economy an estimated $1.5 trillion in 2020 alone. In response, Congress has appropriated billions to combat the crisis, with nearly $11 billion allocated in fiscal years 2017 and 2018.
Unequal Burden: Widening Disparities
The crisis doesn’t affect all communities equally, and disparities have widened in recent years.
Between 2021 and 2022, age-adjusted overdose death rates increased for American Indian and Alaska Native, Black non-Hispanic, Hispanic, and Asian non-Hispanic people. In both 2022 and 2023, the highest rates were among American Indian and Alaska Native people.
These disparities are mirrored in access to care. Black individuals can experience delays of up to five years in getting substance use disorder treatment compared to White peers, and young Black people are less likely to be prescribed medication for opioid use disorder.
In 2023, overdose death rates were highest for adults aged 35-44. Rates are also consistently higher for males than females; in 2019, the male death rate was more than double the female rate.
The Anatomy of Stigma: An Invisible Killer
Behind the staggering crisis statistics lies a powerful, often invisible force: stigma. To effectively combat the epidemic, it’s essential to understand what stigma is, where it comes from, and how it manifests as a formidable recovery barrier.
Defining Stigma
The stigma surrounding substance use disorder is deeply rooted in antiquated and scientifically inaccurate beliefs that addiction is a moral failing, character flaw, or simple lack of willpower. This view contrasts starkly with modern medical understanding of addiction as a chronic, treatable disease that fundamentally alters brain structure and function, affecting impulse control, decision-making, and behavior.
Stigma manifests in three distinct but interconnected forms.
Public Stigma: The Court of Public Opinion
Public stigma refers to negative attitudes and stereotypes held by the general population toward specific groups. For people with opioid use disorder, this stigma is pervasive and powerful.
Research by Johns Hopkins University reveals the depth of these negative public perceptions:
- An overwhelming 78% of Americans believe people addicted to prescription opioids are themselves to blame for the problem
- A similar majority, 72%, believe these individuals simply lack self-discipline
These beliefs translate directly into desire for social distance, with profound implications for community integration and support:
- Only 16% of Americans are willing to have a person using opioids marry into their family
- Only 28% are willing to work closely with them on a job
This public judgment fosters an environment of fear and isolation, making it incredibly difficult for individuals to live openly and seek needed support.
Self-Stigma: The Internalized Voice of Shame
Perhaps the most damaging form is self-stigma, which occurs when individuals from stigmatized groups internalize public negative stereotypes and apply them to themselves.
This internalized shame can lead to what experts call the “why try effect”, the debilitating belief that there’s no point seeking help because one is fundamentally flawed and recovery is hopeless, or because barriers to achieving it seem insurmountable. This paralysis of hope and self-efficacy directly blocks taking the first, crucial step toward recovery.
Structural Stigma: When Bias Becomes Policy
Structural stigma is the most insidious form because it embeds public and self-stigma into society’s fabric. It refers to laws, institutional policies, and cultural norms that systematically, whether intentionally or not, disadvantage people with substance use disorders.
Examples of structural stigma are widespread and impactful:
Discriminatory Laws and Practices: Policies creating barriers to housing, employment, education, and even voting rights for people with substance use histories. Some housing laws explicitly allow agencies to deny services to people with drug use history.
Healthcare System Barriers: Prior authorization requirements and arbitrary lifetime limits on substance use disorder treatment create significant care access hurdles. The fact that addiction treatment has historically been siloed from mainstream medicine reinforces the incorrect notion that it’s not a “real” medical issue.
Underfunding: Disparities in funding for substance use disorder research and treatment compared to other chronic diseases like heart disease or diabetes represent another structural stigma manifestation.
These three stigma forms don’t exist in isolation; they operate as a vicious, self-perpetuating cycle. A structural policy like criminalizing drug possession frames substance use as serious crime rather than health issue. This legal framework reinforces public stigma, solidifying public perception of people who use drugs as “criminals” or “bad people” deserving punishment.
Individuals with substance use disorders internalize these harsh public and legal judgments, leading to self-stigma, feelings of shame, fear, and self-perception as criminals. This internalized shame, coupled with real fear of arrest and other structural consequences, drives behaviors like hiding drug use and avoiding treatment.
These behaviors can lead to negative social outcomes such as overdose, public nuisance, or crime committed to support drug use. Policymakers and the public then point to these outcomes as “proof” that the original punitive structural approach was necessary and justified.
The cycle reinforces itself, creating a system perfectly designed to perpetuate the problem it claims to solve. This demonstrates that simply telling people “addiction is a disease” is insufficient if society’s structures continue treating them like criminals.
How Stigma Obstructs and Kills
Stigma translates into concrete, life-or-death consequences. It’s not an exaggeration to say stigma is a killer. It erects barriers at every recovery journey stage, from preventing individuals from seeking help to undermining care quality and obstructing ability to build stable recovery lives.
The Chilling Effect: A Barrier to Seeking Help
The most direct way stigma kills is by silencing cries for help. Fear of being judged, facing social disapproval, or suffering devastating legal repercussions, such as losing jobs, housing, or parental rights, causes many individuals to hide substance use and avoid seeking treatment.
Data from the National Survey on Drug Use and Health illuminates this chilling effect. In 2021, an estimated 10.4% of people who recognized they needed substance use treatment but didn’t receive it cited fear of negative community attitudes as a primary reason for not seeking care.
This fear creates a tragic and deadly paradox: the people most in need of help are often too afraid to ask for it. This represents a massive missed intervention opportunity. According to the CDC, among overdose deaths in 2023 in a subset of jurisdictions, nearly three out of five individuals had at least one potential opportunity to be linked to care before their fatal overdose.
Stigma closes the door on these opportunities.
Discrimination Within Healthcare
Even for those who overcome fear and seek help, stigma often waits within the very healthcare system supposed to provide care. Bias among health professionals can lead to substandard, ineffective, or even harmful treatment.
This can manifest as “discriminative nursing care,” where patients with opioid use disorder are treated differently from other patients. Their pain reports may be dismissed or undertreated, and they may be pejoratively labeled as “drug-seeking” in medical charts, a label that can follow them throughout their healthcare journey.
Crucially, stigma also blocks access to the most effective, evidence-based treatments. Medications for Opioid Use Disorder (MOUD), including methadone, buprenorphine, and naltrexone, are recognized by the National Academy of Sciences, Engineering, and Medicine as the gold standard of care.
These medications are proven safe and effective, and studies show they can cut overdose death risk by half or more. Yet they remain severely underutilized, largely due to pervasive and false beliefs, held by the public and some healthcare providers, that using these medications is simply “substituting one addiction for another” or serves as a “crutch.”
This stigma against life-saving medicine directly contributes to preventable deaths.
Barriers to Recovery Life: Housing and Employment
Stigma’s destructive influence doesn’t end when people stop using substances. It follows them into recovery, creating significant obstacles to securing stable life foundations: jobs and homes.
Employment: A steady job powerfully motivates maintaining recovery. However, workplace stigma is a major hurdle. A National Safety Council survey found that 75% of employers feel their workplace has been impacted by the opioid crisis, yet only 17% feel well-prepared to deal with it.
This lack of preparedness, combined with stigma, can lead to discriminatory hiring practices and reluctance to hire or support employees in recovery. This occurs despite clear evidence that stable employment improves treatment outcomes and that workers in recovery actually miss fewer work days on average than their peers in the general workforce.
Housing: Safe and stable housing is another critical recovery component. Yet landlords may refuse to rent to individuals with substance use histories. Furthermore, public stigma often fuels intense “Not In My Backyard” (NIMBY) opposition to siting essential services like treatment facilities, harm reduction programs, and recovery housing, making these life-saving resources less accessible to communities that need them most.
The cumulative effect creates a “treatment paradox.” Individuals most severely affected by substance use disorder, and thus most in need of compassionate, evidence-based care, are the very same individuals least likely to receive it because of stigma they face.
When they do manage to access care, that care is often compromised by the same stigmatizing attitudes they sought to overcome. This paradox is amplified for the most effective interventions, such as MOUD and harm reduction services like syringe service programs.
These services are doubly stigmatized, first by their association with drug use, and second by widespread, dangerous misconception that they “enable” rather than save lives. This creates a public health response perversely designed to fail those it’s most intended to serve.
Words as Weapons, Words as Medicine
Language is a powerful tool for dismantling stigma. The words we choose aren’t neutral; they’re active agents that can either reinforce harmful stereotypes or foster an environment of compassion, understanding, and healing.
A conscious, collective shift in our words is a life-saving intervention.
Language Shapes Reality
The connection between language and perception is direct and powerful. When we use terms like “addict,” “junkie,” “abuser,” or “drug habit,” we’re using language that frames the person as the problem. These words are loaded with connotations of moral failing, criminality, and individual blame, and research shows they evoke harsh and judgmental responses from the public.
In contrast, when we adopt medical, person-first language, such as “a person with a substance use disorder”, we fundamentally change the frame. This language separates the individual from their illness, defining addiction as a health condition that a person has, not who they are.
This simple but profound shift promotes more compassionate and helpful responses. Studies confirm that exposure to these different terms significantly alters public perception. Describing someone as “a substance abuser” leads to greater attribution of blame and support for punishment, whereas describing them as “having a substance use disorder” increases support for therapeutic, public health-oriented policies.
The Power of Person-First Language
Person-first language is a linguistic framework that deliberately puts the person before their diagnosis or condition. It originated in the Disability Rights movement as a way to combat dehumanization that comes from defining people by their disabilities.
The principle is simple: we say “a person with diabetes,” not “a diabetic.” Applying this same principle to substance use disorder is a fundamental step in medicalizing the condition and de-stigmatizing the people it affects. It’s a conscious choice to acknowledge a person’s humanity first and their health status second.
A Practical Guide to Reducing Stigma
Adopting new language requires conscious effort and clear understanding of which terms to use and why. Federal agencies including the CDC, National Institute on Drug Abuse, and Substance Abuse and Mental Health Services Administration have developed clear, evidence-based guidelines to help the public, media, and healthcare professionals make this shift.
| Stigmatizing Term to Avoid | Recommended Person-First Alternative | Why It Matters |
|---|---|---|
| Addict, junkie, user, abuser, alcoholic | Person with a substance use disorder (SUD), person with an opioid use disorder (OUD), person in recovery | Separates the person from their disease. Defines addiction as a medical condition someone has, not who they are, reducing blame and negative bias |
| Drug/substance abuse, drug habit | Substance use, misuse (for prescriptions), substance use disorder, risky/hazardous use | “Abuse” and “habit” imply choice and moral judgment, triggering punitive attitudes. “Use” and “misuse” are neutral, medically accurate terms describing behavior without assigning blame |
| Clean, dirty (referring to people or test results) | Testing positive/negative, in recovery, not currently using substances | “Clean” and “dirty” are dehumanizing terms associated with filth and morality. Clinical language like “positive/negative” medicalizes the process and removes judgment, reducing shame |
| Replacement/substitution therapy | Medications for Opioid Use Disorder (MOUD), pharmacotherapy, opioid agonist therapy | “Replacement” falsely suggests trading one addiction for another. “MOUD” accurately describes FDA-approved medications as medical treatment for chronic disease, just like insulin for diabetes |
| Addicted baby, born addicted | Baby with neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS) | A baby cannot be “addicted,” which is a behavioral disorder. They are born with physiological dependence and withdrawal. Accurate medical terminology prevents stigmatizing both infant and mother |
Beyond Words: Framing the Narrative
Reducing stigma requires more than changing individual words; it requires changing the stories we tell about addiction.
Emphasize Societal Causes: It’s crucial to shift narrative focus from individual choice and moral failing to broader societal, environmental, and biological factors that contribute to addiction. This includes discussing how legitimate injury can lead to medically recommended opioid prescription that progresses into opioid use disorder, or how factors like economic despair, trauma, and genetics can increase risk.
Highlighting these external causes makes audiences more likely to support large-scale, societal solutions rather than punitive individual measures.
Incorporate Hope and Solutions: Feelings of hopelessness contribute to stigma. Therefore, messages should consistently emphasize that opioid use disorder is treatable and that recovery is not only possible but common. It’s vital to talk about evidence-based solutions that save lives, such as naloxone and effective treatments like MOUD that help people return to productive and fulfilling lives.
Use Sympathetic Narratives: Stories are powerful tools for humanizing complex issues. Narratives that engage audiences and build empathy can reduce stigma and increase support for evidence-based policies. Research suggests that for addiction, stories told from family member perspectives, such as parents about their children, can be particularly effective at eliciting sympathy and fostering desire to help.
Building a Recovery-Ready Nation: Federal Response
Changing language is a critical first step, but it’s most effective when part of a broader, systemic effort to create an environment that actively supports recovery. Across the federal government, agencies are recognizing that stigma is a primary obstacle to their missions and are implementing coordinated strategies to dismantle it.
The Federal Strategy: Coordinated Response
Multiple federal agencies are working in concert to address stigma as a core component of the national response to the opioid crisis.
HHS Overdose Prevention Strategy: The Department of Health and Human Services has launched an Overdose Prevention Strategy that makes reducing stigma a priority. This strategy promotes harm reduction services, develops educational programs to reduce stigma, and supports community-based prevention and treatment initiatives.
ONDCP National Drug Control Strategy: The White House Office of National Drug Control Policy has outlined a comprehensive strategy that calls for removing barriers to treatment and recovery, including stigma embedded in language and policy. A primary goal for 2024 is promoting adoption of consistent, neutral, science-based, and person-first language across the entire federal government.
SAMHSA’s Educational Initiatives: The Substance Abuse and Mental Health Services Administration is a key leader in educational efforts. SAMHSA provides resources, training programs, and materials for healthcare professionals, community leaders, and the general public on using non-stigmatizing language and understanding addiction as a treatable medical condition.
Creating Recovery-Ready Workplaces
Recognizing that stable employment is a cornerstone of long-term recovery, the U.S. Department of Labor is spearheading a major initiative to help employers transform their workplaces into supportive environments for individuals in or seeking recovery.
The Recovery-Ready Workplace Resource Hub is a central repository of toolkits, sample policies, and educational materials designed to guide employers in this process.
Key strategies promoted by the DOL include:
- Educating leadership and staff about substance use disorder
- Using person-first language in all company communications
- Reviewing and updating human resource policies to be less punitive and more supportive
- Making recovery more visible and accepted by connecting employees with peer support specialists who have lived experience
The Implementation Challenge
While this convergence of federal strategy is significant and promising, a potential “implementation gap” exists. There’s often a disconnect between guidance issued from Washington, D.C., and realities on the ground in local communities, in decisions made by county zoning boards, small business hiring managers, or individual primary care physicians.
Research clearly shows that while federal agencies promote person-first language, stigmatizing terms remain common in clinical settings. While the DOL provides employer toolkits, many remain unprepared to address the issue. And while the federal government supports treatment, local communities often resist placement of the very facilities needed to provide that care.
Bridging this gap is the next critical phase of the national strategy. It requires moving beyond simply publishing resources to actively funding and fostering partnerships with state and local governments, professional associations, educational institutions, and community organizations.
The goal must be ensuring these anti-stigma principles are not just published, but practiced. A true national recovery requires a multi-pronged approach where policy and individual action align.
This includes expanding access to evidence-based care like MOUD, supporting harm reduction services like naloxone distribution and syringe service programs, and reforming discriminatory laws. Ultimately, the success of these policies depends on the public’s willingness to accept them.
That willingness is shaped by perception, and perception is shaped by language. The fight to end the opioid crisis and save American lives begins with the words we choose to use. Every conversation about addiction is an opportunity to either perpetuate deadly stigma or promote life-saving understanding.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.